HIKAL
|
HIKAL Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -3.95 | 7.35 | 5.64 | 6.36 | 13.02 |
| CEPS(Rs) | 9.31 | 18.23 | 15.16 | 15.20 | 20.78 |
| DPS(Rs) | 0.60 | 1.40 | 1.20 | 1.20 | 1.60 |
| Book NAV/Share(Rs) | 97.07 | 102.21 | 96.17 | 91.93 | 86.62 |
| Tax Rate(%) | 37.68 | 26.66 | 27.12 | 25.61 | 26.56 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 12.87 | 17.66 | 14.96 | 12.71 | 17.53 |
| EBIT Margin(%) | -0.95 | 10.70 | 8.51 | 7.59 | 12.86 |
| Pre Tax Margin(%) | -4.57 | 6.66 | 5.35 | 5.21 | 11.25 |
| PAT Margin (%) | -2.85 | 4.88 | 3.90 | 3.87 | 8.26 |
| Cash Profit Margin (%) | 6.71 | 12.11 | 10.49 | 9.26 | 13.19 |
| Performance Ratios | |||||
| ROA(%) | -1.89 | 3.26 | 2.70 | 3.33 | 7.39 |
| ROE(%) | -3.97 | 7.41 | 6.00 | 7.12 | 16.04 |
| ROCE(%) | -0.83 | 9.88 | 7.82 | 8.47 | 15.21 |
| Asset Turnover(x) | 0.66 | 0.67 | 0.69 | 0.86 | 0.89 |
| Sales/Fixed Asset(x) | 0.74 | 0.92 | 1.06 | 1.37 | 1.54 |
| Working Capital/Sales(x) | 8.35 | 9.03 | 8.50 | 7.29 | 9.96 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.35 | 1.08 | 0.94 | 0.73 | 0.65 |
| Receivable days | 102.73 | 105.26 | 101.45 | 79.34 | 86.73 |
| Inventory Days | 73.81 | 62.63 | 63.45 | 58.25 | 55.96 |
| Payable days | 136.71 | 127.05 | 131.02 | 92.70 | 87.68 |
| Valuation Parameters | |||||
| PER(x) | - | 54.42 | 46.99 | 44.34 | 30.92 |
| PCE(x) | 15.79 | 21.94 | 17.47 | 18.55 | 19.37 |
| Price/Book(x) | 1.51 | 3.91 | 2.75 | 3.07 | 4.65 |
| Yield(%) | 0.41 | 0.35 | 0.45 | 0.43 | 0.40 |
| EV/Net Sales(x) | 1.45 | 3.06 | 2.28 | 2.06 | 2.88 |
| EV/Core EBITDA(x) | 10.67 | 17.05 | 15.08 | 15.87 | 16.17 |
| EV/EBIT(x) | -153.26 | 28.57 | 26.76 | 27.13 | 22.37 |
| EV/CE(x) | 1.32 | 2.81 | 2.03 | 2.21 | 3.21 |
| M Cap / Sales | 1.06 | 2.66 | 1.83 | 1.72 | 2.55 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -7.91 | 4.21 | -11.79 | 4.13 | 12.92 |
| Core EBITDA Growth(%) | -30.20 | 23.71 | 2.67 | -24.02 | 5.36 |
| EBIT Growth(%) | -108.14 | 31.01 | -1.02 | -38.56 | 2.95 |
| PAT Growth(%) | -153.74 | 30.46 | -11.20 | -51.16 | 20.55 |
| EPS Growth(%) | -153.74 | 30.46 | -11.35 | -51.16 | 20.55 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.57 | 0.60 | 0.69 | 0.66 | 0.63 |
| Current Ratio(x) | 1.30 | 1.20 | 1.23 | 1.42 | 1.24 |
| Quick Ratio(x) | 0.77 | 0.87 | 0.90 | 0.94 | 0.84 |
| Interest Cover(x) | -0.26 | 2.65 | 2.69 | 3.19 | 8.00 |
| Total Debt/Mcap(x) | 0.38 | 0.15 | 0.25 | 0.22 | 0.14 |
Compare Financial Ratios of peers of HIKAL
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| HIKAL | ₹2,689.8 Cr | 0.1% | 9.9% | -15.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹434,280.0 Cr | -2.4% | -6.2% | 11.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,737.0 Cr | -3.3% | 1.4% | 57.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,129.0 Cr | -4.5% | -4% | 35.9% | Stock Analytics | |
| CIPLA | ₹108,808.0 Cr | -3.6% | -5% | -10.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,170.0 Cr | -0.2% | 2.5% | -3% | Stock Analytics | |
HIKAL Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| HIKAL | 0.1% |
9.9% |
-15.9% |
| SENSEX | -2.3% |
-6.6% |
-12% |
You may also like the below Video Courses
